This trial is testing a new cancer drug, fruquintinib, to see if it is safe and effective when used with tislelizumab to treat patients with locally advanced or metastatic solid tumors. The trial will be conducted in two parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). Part 1 will be open to any-comer solid tumors and will determine the Recommended Phase 2 Dose (RP2D). The RP2D will be administered to four cohorts of patients in Part 2.
3 Primary · 9 Secondary · Reporting Duration: Up to 36 months
112 Total Participants · 2 Treatment Groups
Primary Treatment: Fruquintinib · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: